1. Taiwan, Province of China Stocks

  2. •

    Healthcare

  3. •

    Medical - Diagnostics & Research
AmCad BioMed Corporation

AmCad BioMed Corporation

4188.TWO
AmCad BioMed CorporationTW flagTaipei Exchange
10.70
TWD
-0.10
- -
677.66MMarket Cap

Total Valuation

AmCad BioMed Corporation carries a market capitalization of 677.66M, placing it among publicly traded companies globally. Its enterprise value stands at 644.39M, reflecting the total theoretical takeover cost after accounting for cash holdings and debt obligations.

Market Cap677.66M
Enterprise Value644.39M

Share Statistics

AmCad BioMed Corporation currently has 63.33M shares outstanding.

Shares Outstanding63.33M
Owned by Insiders (%)N/A
Owned by Institutions (%)N/A

Valuation Ratios

The price-to-sales ratio is 30.60, and the price-to-book ratio stands at 2.45.

PE RatioN/A
PS Ratio30.60
PB Ratio2.45
P/TBV Ratio1.72
P/FCF Ratio-19.95
P/OCF Ratio-19.79

Enterprise Valuation

EV / Sales21.17
EV / EBITDAN/A
EV / EBITN/A
EV / FCFN/A

Financial Position

AmCad BioMed Corporation maintains a current ratio of 22.62, meaning it holds 22.6x the short-term assets needed to cover near-term liabilities. The debt-to-equity ratio is 0.79, indicating moderate leverage, while an interest coverage ratio of -999.49 demonstrates limited ability to service its debt obligations.

Current Ratio22.62
Quick Ratio20.48
Debt / Equity0.79
Debt / EBITDA-0.05
Interest Coverage-999.49

Financial Efficiency

Return on Equity (ROE)-13.69
Return on Assets (ROA)-8.46
Return on Invested Capital (ROIC)N/A
Return on Capital Employed (ROCE)N/A
Revenue Per EmployeeN/A
Employee CountN/A
Inventory Turnover0.71

Taxes

Income Tax-15,000.00
Effective Tax RateN/A

Stock Price Statistics

AmCad BioMed Corporation's stock has declined approximately -26.46048% over the past 52 weeks. The 50-day moving average sits at 11.87, while the 200-day moving average is 14.17.

Beta (5Y)N/A
52-Week Price Change-26.46048%
50-Day Moving Average11.87
200-Day Moving Average14.17
Average Volume (20 Days)N/A

Income Statement

Over the trailing twelve months, AmCad BioMed Corporation generated 30.44M in revenue and converted that into -55.72M in net income, yielding earnings per share of -1.13. EBITDA reached -87.95M, while operating income came in at -87.95M.

Revenue30.44M
Gross Profit10.02M
Operating Income-87.95M
Pretax Income-71.40M
Net Income-55.72M
EBITDA-87.95M
EBIT-87.95M
Earnings Per Share (EPS)-1.13

Balance Sheet

AmCad BioMed Corporation holds 371.22M in cash and equivalents against 4.75M in total debt, resulting in a net debt position of -24.60M. Total book value stands at 380.25M, with working capital of 391.87M providing operational flexibility.

Cash & Cash Equivalents371.22M
Total Debt4.75M
Net Debt-24.60M
Equity (Book Value)380.25M
Book Value Per Share6.00
Working Capital391.87M

Cash Flow

AmCad BioMed Corporation produced -47.06M in operating cash flow over the past twelve months. After subtracting -373,000.00 in capital expenditures, free cash flow totaled -47.43M - equivalent to -0.75 per share.

Operating Cash Flow-47.06M
Capital Expenditures-373,000.00
Free Cash Flow-47.43M
FCF Per Share-0.75

Margins

AmCad BioMed Corporation operates with a gross margin of 32.93, reflecting its pricing power and cost economics. The operating margin of -288.97 and net profit margin of -183.06 provide insight into operational efficiency.

Gross Margin32.93
Operating Margin-288.97
Pretax Margin-234.59
Profit Margin-183.06
EBITDA Margin-288.97

Dividends & Yields

Dividend Per ShareN/A
Dividend YieldN/A
Payout RatioN/A
Shareholder Yield0.54
FCF Yield-5.01

Stock Splits

AmCad BioMed Corporation's most recent stock split took place on May 27, 2016 with a 100:103 split ratio.

Last Split Date5/27/2016
Split Ratio100:103

Scores

AmCad BioMed Corporation posts an Altman Z-Score of 25.29, well above the 3.0 threshold that indicates strong financial health and minimal bankruptcy risk.

Altman Z-Score25.29